» Articles » PMID: 27451875

The Clinical Management and Outcomes of Cervical Neuroblastic Tumors

Overview
Journal J Surg Res
Specialty General Surgery
Date 2016 Jul 26
PMID 27451875
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although patients with peripheral neuroblastoma (NB; pelvic and thoracic) typically have better outcomes and less aggressive disease compared with patients with abdominal disease, little has been published with regard to the management and outcomes of patients with cervical NB. Herein, we sought to determine the characteristics of cervical neuroblastic tumors and the effect of extent of resection on survival and outcomes.

Methods: We performed a retrospective review of 325 children with neuroblastic tumors at Children's Hospital Los Angeles over a 15-y period (January 1990-February 2015). Data collected from the medical record included location of tumor, age at diagnosis, age at resection, extent of resection, chemotherapy course, International Neuroblastoma Staging System stage, histologic International Neuroblastoma Pathology Classification, and MYCN amplification, a poor prognostic marker. Outcome variables included postoperative complications and overall survival.

Results: Twelve patients (3.6%) were found to have cervical neuroblastic tumors (nine NBs, one ganglioneuroblastoma, and two ganglioneuromas). All had favorable histology, and none (0/12) had MYCN amplification. Of the NB patients, four of nine patients underwent resection, whereas the other five underwent biopsy followed by chemotherapy or observation alone. Of the 12 total patients, six underwent gross total resection, four (67%) of which developed complications. At a median follow-up of 4.4 y, there were no recurrences or deaths.

Conclusions: Cervical neuroblastic tumors represent favorable lesions with good outcomes similar to other peripheral neuroblastic tumors. In our study, survival was excellent regardless of extent of tumor resection. Based on our data, we recommend a minimally aggressive surgical approach in managing children with cervical neuroblastic tumors.

Citing Articles

Posttreatment complications in pediatric cervical neuroblastoma: A retrospective case series at a tertiary cancer center.

Lopez J, Subramanian T, Durell J, Levyn H, Wong R, Shah J J Surg Oncol. 2023; 129(2):219-223.

PMID: 37850570 PMC: 11637323. DOI: 10.1002/jso.27482.


International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Abib S, Chui C, Cox S, Abdelhafeez A, Fernandez-Pineda I, Elgendy A Ecancermedicalscience. 2022; 16:1356.

PMID: 35510137 PMC: 9023308. DOI: 10.3332/ecancer.2022.1356.


Adrenal ganglioneuroma: Prognostic factors (Review).

Sandru F, Dumitrascu M, Petca A, Carsote M, Petca R, Oproiu A Exp Ther Med. 2021; 22(5):1338.

PMID: 34630692 PMC: 8495554. DOI: 10.3892/etm.2021.10773.


Anesthesia in Children with Neuroblastoma, Perioperative and Operative Management.

Tognon C, Pulvirenti R, Fati F, De Corti F, Viscardi E, Volpe A Children (Basel). 2021; 8(5).

PMID: 34068896 PMC: 8156024. DOI: 10.3390/children8050395.


A population-based analysis of clinical features and lymph node dissection in head and neck malignant neurogenic tumors.

Fang X, Wang S, Zhao J, Zhang Y, Zhang J, Li Y BMC Cancer. 2021; 21(1):598.

PMID: 34030648 PMC: 8146628. DOI: 10.1186/s12885-021-08307-4.

References
1.
Sung K, Yoo K, Koo H, Kim J, Cho E, Seo Y . Neuroblastoma originating from extra-abdominal sites: association with favorable clinical and biological features. J Korean Med Sci. 2009; 24(3):461-7. PMC: 2698193. DOI: 10.3346/jkms.2009.24.3.461. View

2.
Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

3.
Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

4.
Bowman L, Castleberry R, Cantor A, Joshi V, Cohn S, SMITH E . Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997; 89(5):373-80. DOI: 10.1093/jnci/89.5.373. View

5.
Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View